Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 400-404

  Kofoed, Kristian ^a   Zalounina, Alina ^b   Andersen, Ove ^a   Lisby, Gorm ^a   Paul, Mical ^c,d   Leibovici, Leonard ^c,d   Andreassen, Steen ^b  

^a Mental Health Services CPH   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Computerized decision support system; Empirical antimicrobial therapy; Severe infections

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERTAPENEM; PENICILLIN G; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREAT DECISION SUPPORT SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIA; BACTERIAL INFECTIONS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DECISION SUPPORT SYSTEMS, CLINICAL; DENMARK; DRUG RESISTANCE, BACTERIAL; FEMALE; HEALTH SERVICES RESEARCH; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 58849139233     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn504     Document Type: Article

References (14)

1. Sands K, Bates D, Lanken P et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-40.
2. Alberti C, Brun-Buisson C, Goodman S et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003; 168: 77-84.
3. Kumar A, Roberts D, Wood K et al. Duration of hypertension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
4. Paul M, Andreassen S, Tacconelli E et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: Cluster randomized trial. J Antimicrob Chemother 2006; 58: 1238-45.
5. Leibovici L, Shraga I, Drucker M et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-86.
6. Fraser A, Paul M, Almanasreh N et al. Benefit of appropriate empirical antibiotic treatment: Thirty-day mortality and duration of hospital stay. Am J Med 2006; 119: 970-6.
7. Goldmann DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275: 234-40.
8. Wilson A, Bint A, Glenny A et al. Meta-analysis and systematic review of antibiotic trials. J Hosp Infect 1999; 43 Suppl: S211-4.
9. Andreassen S, Leibovici L, Paul M et al. A probabilistic network for fusion of data and knowledge in clinical microbiology. In: Husmeier D, Dybowski R, Roberts S, eds. Probabilistic Modeling in Bioinformatics and Medical Informatics. London: Springer, 2005; 451-72.
10. Leibovici L, Samra Z, Konigsberger H et al. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807-12.
11. Kofoed K, Eugen-Olsen J, Petersen J et al. Predicting mortality in patients with systemic inflammatory response syndrome: An evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008; 27: 375-83.
12. Kofoed K, Andersen O, Kronborg G et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: A prospective study. Crit Care 2007; 11 R38.
13. Bone R, Balk R, Cerra F et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 1644-55.
14. Konradsen HB, Kaltoft MS. Invasive pneumococcal infections in Denmark from 1995 to 1999: Epidemiology, serotypes, and resistance. Clin Diagn Lab Immunol 2002; 9: 358-65.